The research found that eight out of the nine individuals in the GA2 group were effectively protected against contracting malaria.
None of the individuals in the placebo group were protected, and just one out of eight took part in the GA1 group. Now, in a bigger human experiment, the Dutch researchers want to repeat their findings.
“These findings represent a significant step forward in malaria vaccine development,” London School of Hygiene and Tropical Medicine.
Immunologist Julius Hafalla told Nature. “The ongoing global malaria burden makes the development of more effective vaccines a critical priority.”
In September 2023, the Gates Foundation awarded Leiden University Medical Centre a $1,578,317 grant to study “population and geographic factors affecting.
Response to malaria vaccines in endemic countries.” The Gates Foundation awarded the centre a funding in November with the goal of “developing next generation malaria vaccine candidates.
